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Summary
Background Observational evidence suggests that community-based services for people with schizophrenia can be 
successfully provided by community health workers, when supervised by specialists, in low-income and middle-
income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the 
eﬀ ectiveness of a collaborative community-based care intervention with standard facility-based care.
Methods We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 
and Dec 31, 2010. Patients aged 16–60 years with a primary diagnosis of schizophrenia according to the tenth edition 
of the International Classiﬁ cation of Diseases, Diagnostic Criteria for Research (ICD-10-DCR) were randomly assigned 
(2:1), via a computer-generated randomisation list with block sizes of three, six, or nine, to receive either collaborative 
community-based care plus facility-based care or facility-based care alone. Randomisation was stratiﬁ ed by study site. 
Outcome assessors were masked to group allocation. The primary outcome was a change in symptoms and disabilities 
over 12 months, as measured by the positive and negative syndrome scale (PANSS) and the Indian disability evaluation 
and assessment scale (IDEAS). Analysis was by modiﬁ ed intention to treat. This study is registered as an International 
Standard Randomised Controlled Trial, number ISRCTN 56877013.
Findings 187 participants were randomised to the collaborative community-based care plus facility-based care group 
and 95 were randomised to the facility-based care alone group; 253 (90%) participants completed follow-up to 
month 12. At 12 months, total PANSS and IDEAS scores were lower in patients in the intervention group than in 
those in the control group (PANSS adjusted mean diﬀ erence –3·75, 95% CI −7·92 to 0·42; p=0·08; IDEAS –0·95, 
−1·68 to −0·23; p=0·01). However, no diﬀ erence was shown in the proportion of participants who had a reduction of 
more than 20% in overall symptoms (PANSS 85 [51%] in the intervention group vs 44 [51%] in the control group; 
p=0·89; IDEAS 75 [48%] vs 28 [35%]). We noted a signiﬁ cant reduction in symptom and disability outcomes at the 
rural Tamil Nadu site (−9·29, −15·41 to −3·17; p=0·003). Two patients (one in each group) died by suicide during the 
study, and two patients died because of complications of a road traﬃ  c accident and pre-existing cardiac disease. 
18 (73%) patients (17 in the intervention group) were admitted to hospital during the course of the trial, of whom 
seven were admitted because of physical health problems, such as acute gastritis and vomiting, road accident, high 
fever, or cardiovascular disease.
Interpretation The collaborative community-based care plus facility-based care intervention is modestly more eﬀ ective 
than facility-based care, especially for reducing disability and symptoms of psychosis. Our results show that the study 
intervention is best implemented as an initial service in settings where services are scarce, for example in rural areas.
Funding Wellcome Trust.
Copyright © Chatterjee et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
The absence of accessible services for people with 
schizophrenia in low-income and middle-income 
countries contributes to the substantial public health 
burden of schizophrenia; poor health and social 
outcomes, including poverty;1 social exclusion attributable 
to stigma and discrimination; and human rights 
violations in these settings.2 In many high-income 
countries, clinical and social services for people with 
schizophrenia are coordinated by specialist community-
based multidisciplinary teams. However, such specialist 
services are not presently feasible in low-income and 
middle-income countries because of serious human and 
ﬁ nancial resource constraints. Hence, development of 
alternative methods for provision of accessible, 
community-based services for people with schizophrenia 
within these countries is a global public health priority.3
Increasing observational evidence from low-income 
and middle-income countries shows that the community-
based rehabilitation method of services, delivered through 
community health workers working with mental health 
specialists, might be a feasible way to deliver services that 
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improve clinical and social outcomes of people with 
schizophrenia.4 However, such evidence from randomised 
controlled trials in these settings is scarce.
We did the COmmunity care for People with 
Schizophrenia in India (COPSI) study to compare the 
clinical eﬀ ectiveness of two service delivery methods for 
people with schizophrenia and their caregivers. We 
postulated that a combination of facility-based care and 
collaborative community-based care would be more 
eﬀ ective than facility-based care alone for people with 
moderate to severe schizophrenia for changes in 
symptoms and disabilities.
Methods
Study design and patients
A description of the study design, methods, and analysis 
plan has been published elsewhere.5 We undertook this 
multicentre, parallel-group, randomised controlled trial 
between Jan 1, 2009 and Dec 31, 2010, at three sites in 
India (four subdistricts of Kancheepuram district, Tamil 
Nadu; Goa; and Satara District in Maharashtra). The 
Tamil Nadu site was rural with no locally accessible 
mental health services; Satara and Goa had a mixed 
urban and rural population with easier access to specialist 
care in public and private facilities.
Because COPSI was designed as a pragmatic 
randomised trial, we used broad inclusion criteria. 
Eligible patients aged 16–60 years had a primary 
diagnosis of schizophrenia according to the tenth edition 
of the International Classiﬁ cation of Diseases, Diagnostic 
Criteria for Research (ICD-10-DCR); an illness duration 
of at least 12 months of at least moderate severity overall, 
as rated by the clinical global impression-schizophrenia 
scale;6 and intended to reside in the study regions for 
12 months. In Tamil Nadu, a two-staged, key-informant 
community survey was done to identify participants who 
met inclusion criteria, whereas in Goa and Satara, 
participants were recruited from the clinical practices of 
the collaborating psychiatrists. Thus, we used two 
pathways for recruitment: (1) people with schizophrenia 
from within the existing caseloads, and (2) people with 
schizophrenia who presented for care at treatment 
facilities for the ﬁ rst time. Across the study sites, 
collaborating psychiatrists screened people with a 
primary ICD-10-DCR diagnosis of schizophrenia for 
eligibility. For each participant, one primary caregiver 
was identiﬁ ed and asked for consent to participate. All 
eligible participants were provided with an overview of 
the study in the relevant local language before seeking 
informed consent (appendix).
The COPSI-informed consent procedure was undertaken 
by a team of trained interviewers using a ﬂ ipchart to enable 
people who were not literate to understand the implications 
and risks of participation. We enrolled participants and 
caregivers if both provided written or independently 
witnessed (for people who were not literate) informed 
consent. Ethics approval was obtained from the 
institutional review boards of Sangath and SCARF, and 
from King’s College London and the London School of 
Hygiene & Tropical Medicine. The trial monitoring 
committee provided additional oversight of the trial.
Randomisation and masking
Patients were randomly assigned in a 2:1 ratio, via 
computer-generated randomisation list with block sizes 
of three, six, or nine, to receive either collaborative 
community-based care plus facility-based care or facility-
based care alone. Randomisation was stratiﬁ ed by study 
site. For each site, the randomisation list was generated 
independently by the trial statistician and transferred to 
the site data manager before recruitment. The data 
manager had no role in the recruiting of participants and 
held the passwords for the randomisation lists; individuals 
recruiting participants did not have access to the 
randomisation lists or the passwords.
Outcome assessors were masked to group allocation. 
Because neither participants nor the family caregivers 
were masked to their allocation status at the 6 month and 
12 month interviews, unmasking was possible during the 
outcome assessments. To minimise this possibility, we 
kept the research and intervention teams physically 
separate during the trial, asked participants and 
caregivers ﬁ rst at the time of assessments to not disclose 
whether they had received home visits from the 
community health worker, and the primary outcome 
measures (positive and negative syndrome scale [PANSS] 
and the Indian disability evaluation assessment scale 
[IDEAS]) were completed ﬁ rst. Instances of unmasking 
were recorded by the researchers. If unmasking 
happened at the time of the 6 month assessment, a 
separate researcher undertook the 12 month assessments. 
Facility-based care was available to participants in both 
study groups; thus, treating psychiatrists were aware of 
the allocation status of participants.
Procedures
The collaborative community-based care intervention 
was motivated by our experience with development of a 
similar intervention in a rural resource-poor setting in 
India.4 This intervention was further reﬁ ned in iterative 
formative phases as recommended by guidelines from 
the Medical Research Council for development and 
assessment of complex interventions. Initially, we 
selected components of the intervention from a 
systematic review of the scientiﬁ c literature. To help 
match the concerns of people with schizophrenia and 
their caregivers with the intervention components, we 
additionally identiﬁ ed outcomes that mattered to these 
individuals. We undertook further pilot work to address 
operational challenges in delivery of the interventions. 
This process identiﬁ ed challenges in delivery of the 
home-based sessions, organisation of the supervision for 
community health workers as planned, and the need for 
a simpler set of information materials. This identiﬁ cation 
For the ﬂ ipchart element of the 
manual see http://www.
sangath.com/images/ﬁ le/
COPSI%20intervention%20
ﬂ ipchart.pdf
See Online for appendix
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led to adaptations such as speciﬁ c strategies to address 
planning for the home-based sessions, the risk of 
attrition, and the development of material such as the 
ﬂ ipchart element of the manual to help community 
health workers communicate the contents of the 
psychoeducation sessions.
The collaborative community-based care intervention 
was designed to promote collaboration between the 
person with schizophrenia, their caregivers, and the 
treatment team to deliver a ﬂ exible, individualised, and 
needs-based intervention.7 The intervention was 
delivered by community health workers who had at least 
10 years of schooling and good interpersonal skills. These 
workers were systematically trained over 6 weeks and 
assessed for competence with the intervention manual.
To meet the prespeciﬁ ed quality assurance and ﬁ delity 
standards, community health workers at each site were 
supervised by intervention coordinators. Coordinators 
were psychiatric social workers trained in the necessary 
supervision and monitoring skills. The treating 
psychiatrists supervised the intervention delivery 
through quarterly team reviews and ongoing supervision 
of community health workers. Continued education and 
training of the health workers was an essential part of 
the intervention. Panel 1 describes components of the 
collaborative community-based care intervention. To 
standardise the intervention across sites, the COPSI 
study team developed a manual to be used ﬂ exibly 
according to the individual needs of participants. The 
intervention was delivered in three phases: (1) the 
intensive engagement phase (0–3 months), including 
six to eight home visits made by community health 
workers; (2) the stabilisation phase (4–7 months), with 
sessions delivered once every 15 days; and (3) the 
maintenance phase (8–12 months), with sessions 
delivered once a month.
The control group received the facility-based care 
indication to show the crucial diﬀ erences compared with 
collaborative community-based and facility-based care—
ie, the location of services and the use of community 
health workers. Facility-based care represents the usual 
care provided by specialist mental health practitioners 
for people with schizophrenia and their families in India. 
The operational aspects of the facilities diﬀ ered across 
trial sites. In Goa there were four private clinics, 
supported by inpatient facilities. In Satara, the four 
private psychiatrists operated as a group practice from 
one facility and shared an inpatient service. In Tamil 
Nadu, care was from a clinical team consisting of 
psychiatrists and assistants at a designated facility some 
distance away from most patients; this service is similar 
to those in many rural areas in India.
Although the sites varied somewhat, the content of the 
control-based care provided was similar. Brieﬂ y, the 
intervention was delivered by the psychiatrists through 
consultations, lasted 10–15 min, and all people with 
schizophrenia were prescribed antipsychotic drugs. 
Psychiatrists also provided information about the illness, 
encouraged adherence to drugs, and discussed speciﬁ c 
concerns raised.
Outcomes
The primary outcome was a change in symptoms and 
disabilities in 12 months. Secondary outcomes were 
adherence to antipsychotic treatment and experiences of 
stigma and discrimination. For caregivers of people with 
Panel 1: Components of the collaborative community-based 
care intervention
• Structured needs assessments at enrolment and every 
3 months thereafter to develop matched individualised 
treatment plans
• Structured clinical reviews by treating team and supervision 
for community health workers
• Psychoeducational information for participants and 
caregivers
• Adherence management strategies
• Strategies of health promotion to address physical health 
problems in participants
• Individualised rehabilitation strategies to improve the 
personal, social, and work functioning of participants
• Speciﬁ c eﬀ orts with participants and caregivers to deal 
with experiences of stigma and discrimination
• Linkage to self-help groups and other methods of user-led 
support
• Networks with community agencies to address social 
issues, to help with social inclusion, access to legal 
beneﬁ ts, and employment opportunities
Figure: Trial proﬁ le
1021 participants assessed for eligibility
282 randomised
739 excluded
569 did not meet inclusion criteria
89 declined to participate
81 for other reasons
95 assigned to facility-based care†
86 analysed
9 lost to follow-up
6 refused
1 was not found
2 had died
187 assigned to collaborative 
community-based care 
plus facility-based care*
167 analysed
20 lost to follow-up
10 refused
8 were not found 
or had moved
2 had died
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schizophrenia, the secondary outcomes were changes in 
knowledge and attitudes about the illness, changes in felt 
burden of caring, and experiences of stigma and 
discrimination. Additionally, we included an analysis of 
health economics with an assessment of the costs and 
cost-eﬀ ectiveness of the collaborative community-based 
care and facility-based care intervention compared with 
facility-based care alone.
Symptoms were measured at baseline and 12 months 
with the PANSS,8 which has been previously used in 
India. PANSS comprises 30 items measuring positive 
and negative symptoms and general psychopathology. 
To assess disability, we used the IDEAS at baseline, 6, 
and 12 months. IDEAS has been validated in India9 
and measures self-care, interpersonal activities, 
communication and understanding, and work.10
The trial protocol has full details of the measures used 
for the secondary outcomes.5 In brief, we used the 
following scales: a 5-point ordinal scale developed for 
the study (adherence); discrimination and stigma scale,11 
the alienation subscale of the internalised stigma of 
mental illness scale,12 and an item on willingness to 
disclose the illness (stigma and discrimination of 
participants); the knowledge about schizophrenia 
interview scale13 (caregiver knowledge and attitudes); the 
burden assessment schedule (family burden of caring);14 
the relevant section of the family interview schedule;15 
and a modiﬁ ed version of the item on willingness to 
disclose the illness (caregiver experiences of stigma and 
discrimination); and cost of illness schedule (health 
economic outcomes).16
Statistical analysis
On the basis of data from the only relevant study in India,17 
we assumed that an absolute diﬀ erence of a 20% reduction 
in mean PANSS total score, from 65 to 52 (SD 10), would 
be highly clinically signiﬁ cant. The intraclass correlation 
between sites in the facility-based care group was 
estimated as 0·05; for the intervention group (which also 
includes between-community health worker clustering), 
this correlation was assumed to be 0·1. These estimates 
were conservative on the basis of a review of primary care 
variables.18 An allocation ratio of 2:1 was used to allow for 
the between-health worker clustering eﬀ ect in the 
intervention group.19 The estimated required total sample 
size of 241 was increased to 282 to allow for 15% attrition 
during the study. With α=0·05, this sample size had 80% 
power to detect an eﬀ ect size of 0·8 (diﬀ erence in PANSS 
score of 7·2 units [SD 9]), and 90% power to detect an 
eﬀ ect size of 1 (diﬀ erence in PANSS score of 9 units [9]). 
We obtained data for IDEAS and adherence with palmtop 
computers, whereas PANSS data were obtained with pen 
and paper. Analyses followed the prespeciﬁ ed data analysis 
plan and no interim analyses were done. All analyses used 
Stata version 11.2.
We analysed descriptive summaries of sociodemo-
graphic and clinical data for all participants at baseline, 
and for outcome measures at baseline, and at 6 month 
and 12 month follow-up points, and compared them by 
group. PANSS and IDEAS scores used were total score, 
domain sub-scores, and proportion of patients improving 
by more than 20% from baseline. For PANSS, a value 
of 30 was ﬁ rst subtracted from the proportion of patients 
improving by more than 20% from baseline because this 
is the minimum total score. We used histograms of data 
for the control group to assess normality of the distribution 
of the data and to identify outliers.
For inferential analysis, participants were analysed by 
original randomised group (a modiﬁ ed intention-to-treat 
approach). We used linear mixed-eﬀ ect regression to 
analyse the intervention eﬀ ect on continuous outcomes 
(the 12 month PANSS and IDEAS total scores), adjusted 
for baseline scores and site as ﬁ xed terms, and a random 
Collaborative 
community-based care 
plus facility-based care
(n=187)
Facility-based care 
(n=95)
Age (years) 36·2 (10·2) 35·6 (10·4)
Sex
Women 86 (46%) 47 (49%)
Education
None 11 (6%) 6 (6%)
Primary school (up to 5th standard) 26 (14%) 14 (16%)
Middle school (6th to 8th standard) 30 (16%) 14 (16%)
High school (9th to 12th standard) 81 (43%) 39 (43%)
College or above 34 (18%) 17 (19%)
Missing 5 (3%) 5 (5%)
Occupation
Not income generating 138 (75%) 66 (69%)
Income generating 38 (21%) 25 (26%)
Other* 8 (4%) 4 (4%)
Marital status
Married 87 (47%) 34 (36%)
Single 77 (42%) 44 (46%)
Separated or divorced 15 (8%) 8 (8%)
Widow 5 (3%) 9 (9%)
Residence
Rural 132 (71%) 63 (66%)
Urban 55 (29%) 32 (34%)
Caste
Schedule caste 46 (25%) 20 (21%)
Schedule tribe 4 (2%) 2 (2%)
Other backward caste 45 (24%) 28 (29%)
None of the above 74 (40%) 30 (32%)
Unknown 18 (10%) 15 (16%)
Duration of illness (years) 7·0 (3·0–11·0) 6·25 (3·1–10·8)
Treatment status at entry
Ongoing treatment at facility 96 (57%) 49 (56%)
First contact with facility 71 (43%) 39 (44%)
Data are mean (SD), n (%), or median (IQR). *Student or retired.
Table 1: Baseline characteristics
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eﬀ ect to allow for community health workers clustering 
in the intervention group. We used mixed-eﬀ ects logistic 
regression to analyse the intervention eﬀ ect on binary 
outcomes, and mixed-eﬀ ects ordinal logistic regression 
for ordered categorical outcomes. For the IDEAS score, 
we did a longitudinal analysis, including both 6 month 
and 12 month outcomes, using a random-eﬀ ects model 
including a time × treatment term allowing for 
intervention eﬀ ect changes over time. The eﬀ ect of 
adherence was assessed by categorisation of self-reported 
adherence at 12 months as complete or most of the time, 
and including an interaction term between adherence 
and intervention group. No imputation was made 
because missing data were fewer than the predeﬁ ned 
threshold speciﬁ ed in the trial protocol.
Costs were reported in Indian Rupees (INR) and also 
International Dollars (I$) with an exchange rate of INR 
19·13 to I$1. Total costs were compared and bootstrapped 
CIs computed. We calculated incremental cost-
eﬀ ectiveness ratios to show the extra cost for collaborative 
community-based care and facility-based care to achieve 
an extra unit improvement in the primary outcomes.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The ﬁ gure shows the trial proﬁ le. 187 eligible patients were 
randomised to the collaborative community-based care 
and facility-based care group (70 in Tamil Nadu, 60 in Goa, 
and 57 at Satara) and 95 were randomised to the facility-
based care group (35 in Tamil Nadu, 32 in Goa, and 28 at 
Satara). Recruitment and follow-up took place between 
Oct 1, 2009, and Dec 31, 2011. Most participants in both 
groups (167 [89%] in the intervention group and 86 [91%] 
in the control group) were available at 12 month 
assessment. 23 interviews (19 [83%] in the intervention 
group and four [17%] in the control group) were unmasked 
during the 6 months of data collection, whereas 
22 interviewers (20 [91%] vs two [9%]) were unmasked at 
the 12 month point. The sociodemographic and clinical 
characteristics of participants were similar between the 
treatment groups (table 1).
We monitored the intervention for ﬁ delity and quality 
assurance purposes by collecting key process indicators 
for both groups. The mean number of sessions with 
community health workers that were received by 
participants in the community-based care and facility-
based care group was 17·97 (SD 7·12, 95% CI 
16·94–19·00), and 169 (90%) received the predeﬁ ned 
minimally eﬀ ective 12 sessions. The mean number of 
contacts with a treating psychiatrist was ten 
(95% CI 9·53–10·89) in the intervention group and 
eight (6·98–9·11) in the control group. At 12 months, we 
noted a reduction in overall symptoms in both groups 
(table 2). Total PANSS score was lower at 12 months in 
patients in the intervention group than in those in the 
control group, after adjustment for baseline PANSS 
scores and site (table 2). However, no diﬀ erence was 
shown in the proportion of participants who had a 
reduction of more than 20% in overall symptoms (85 
[51%] vs 44 [51%]; p=0·89).
The eﬀ ect was stronger for overall disability (table 2). A 
post-hoc analysis of the odds of patients improving by 
20% or more on the IDEAS total score showed that more 
people improved by this extent in the intervention group 
than in the control group (75 [48%] vs 28 [35%], adjusted 
odds ratio [OR] 1·84, 95% CI 0·97–3·46; p=0·06). We 
noted clear site eﬀ ects in relation to the primary 
outcomes (table 2). For the PANSS primary symptom 
outcome, a signiﬁ cant symptom reduction was shown 
for Tamil Nadu (p=0·003), but no signiﬁ cant change was 
reported for the Goa and Satara sites (table 2). The same 
pattern was shown for the IDEAS disability outcome, 
with a clear disability reduction in Tamil Nadu (p=0·01), 
but no change was identiﬁ ed at the other two sites 
(table 2).
Participants in the intervention group had lower scores 
across all subdomains of symptoms and disabilities 
measured at 12 months than did those in the intervention 
group (table 3). Scores reached statistical signiﬁ cance 
only for the general psychopathology domain in the 
PANSS and the self-care domain in the IDEAS (table 3). 
The community-based care and facility-based care 
intervention was more eﬀ ective in reducing total 
Collaborative 
community-
based care
Facility-
based care
Collaborative 
community-based care 
vs facility-based care*
p value
All sites
PANSS score
Baseline 76·28 (20·19) 74·65 (19·42) ·· ··
12 months 66·62 (17·25) 70·53 (17·94) −3·75 (−7·92 to 0·42) 0·08
IDEAS score
Baseline 6·79 (3·90) 6·13 (3·60) ·· ··
12 months 5·68 (3·54) 6·40 (3·82) −0·95 (−1·68 to −0·23) ··
Individual sites
PANSS score
Tamil Nadu 63·5 (13·6) 73·0 (17·8) −9·29 (−15·41 to −3·17) 0·003
Goa 73·0 (18·0) 75·9 (17·0) −2·59 (−10·20 to 5·01) 0·50
Satara 63·8 (19·1) 61·6 (16·4) 1·72 (−5·86 to 9·30) 0·66
IDEAS score
Chennai 7·78 (2·57) 9·23 (2·76) −1·76 (−2·80 to −0·72) 0·001
Goa 5·78 (3·30) 5·64 (3·31) 0·01 (−1·43 to 1·45) 0·98
Satara 2·80 (2·86) 3·85 (3·27) −0·96 (−2·33 to 0·40) 0·17
Data are mean (SD) or adjusted mean diﬀ erence (95% CI), unless otherwise indicated. PANSS=positive and negative 
syndrome scale. IDEAS=Indian disability evaluation assessment scale. *Adjusted for baseline score and site.
Table 2: Adjusted PANSS and IDEAS total scores over 12 months
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disability scores at 12 months than at 6 months, after 
adjustment for baseline score and site (p=0·01; appendix).
The appendix shows the association of complete or 
almost complete adherence between the treatment groups. 
At 12 months, 153 (61%) participants reported complete 
adherence to drugs, and a further 57 (23%) reported 
adherence most of the time. At both 6 months and 
12 months, participants in the intervention group were 
signiﬁ cantly more likely to report adherence all or most of 
the time to prescribed drugs compared with those in the 
control group (appendix). We noted a similar eﬀ ect on 
adherence reported by caregivers at 12 months (appendix).
The study had low power to detect intervention eﬀ ects 
by level of adherence, but there was a trend towards 
reduced symptoms in patients who had good adherence to 
drugs (PANSS adjusted mean diﬀ erence –3·85 [SE 6·94] 
in patients with good adherence vs −0·52 [5·13] in those 
with poor adherence; p value for eﬀ ect modiﬁ cation 
between adherence and treatment group=0·56). For 
IDEAS, we noted a similar, but smaller, trend of greater 
improvement in patients with good adherence compared 
with those with poor adherence (–1·14 [SE 1·33] vs 0·09 
[0·90]; p value for eﬀ ect modiﬁ cation=0·21).
Participants in the intervention group did not report 
lower stigma than did those in the control group 
(adjusted OR for any reported alienation 1·15, 
95% CI 0·66–2·02; table 4). Moreover, participants in the 
intervention group were more likely to be unwilling to 
disclose their illness at 12 months than were those in the 
control group (table 4). However, we noted clinically and 
statistically signiﬁ cant reductions in reported experiences 
of stigma and discrimination from baseline to 12 months 
in both groups for three of the four outcome measures—
eg, the proportion of participants reporting any negative 
discrimination (p=0·004; table 4).
We noted no evidence of an intervention eﬀ ect on mean 
total score on the knowledge about schizophrenia interview 
scale (adjusted mean diﬀ erence 0·34, 95% CI −0·28 to 0·96), 
or on burden (−0·04, −0·18 to 0·11), reported stigma (1·35, 
0·72–2·53), or willingness to disclose their family 
members’ illness (1·43, 0·80–2·53).
The mean number of sessions in the intervention 
group was 17·1 (6·9) with slight variation between sites 
(appendix). Travel times were highest in Tamil Nadu 
(appendix). Costs of input from the community health 
workers were exceeded by the costs of supervision 
(appendix). Total intervention costs were highest in Goa 
and lowest in Satara (appendix). Other service costs 
varied between sites with the highest for participants in 
in the intervention group in Goa (appendix). Total costs 
in the 12 months of follow-up were highest for 
participants in the intervention group, mainly because of 
staﬀ  supervision costs (appendix). The mean diﬀ erence 
between the two groups adjusted for baseline was 
INR 9427 (95% CI 6584–12 224), which is equivalent to 
I$493 (344–639). The incremental cost-eﬀ ectiveness ratio 
(ICER), based on the PANSS, is deﬁ ned as the 
incremental cost of community-based care and facility-
based care group compared with facility-based care alone 
(INR 9427) divided by the incremental reduction in 
symptoms (3·75). This ratio shows that a cost of INR 2514 
(I$131) is needed to achieve a 1 point reduction on the 
PANSS. The ICER based on the IDEAS is INR 9365 
divided by 0·95—ie, INR9923 (I$519) to achieve a 1 point 
reduction on the IDEAS (appendix).
Four patients died during the study. Two (50%) of these 
deaths were because of suicide (one in each treatment 
group), whereas the other two (50%) were due to 
complications of a road traﬃ  c accident and pre-existing 
cardiac disease. 18 (73%) patients were admitted to 
hospital during the course of the trial; of these, 17 were in 
the intervention group. Seven (39%) of these admissions 
were related to physical health problems, such as acute 
Collaborative 
community-
based care
Facility-
based care
Collaborative 
community-
based care vs 
facility-based care 
(adjusted mean 
diﬀ erence [SE])
95% CI
PANSS*
Positive subscale
Baseline 17·84 (7·07) 16·68 (5·91) ·· ··
12 months 13·98 (5·68) 15·03 (6·91) −1·45 (0·93) −3·27 to 0·38
Negative subscale
Baseline 21·47 (7·55) 21·24 (7·54) ·· ··
12 months 19·59 (6·95) 20·13 (6·11) −0·50 (0·77) −2·00 to 1·00
General subscale
Baseline 36·97 (10·29) 36·73 (9·89) ·· ··
12 months 32·88 (8·76) 35·36 (9·81) −2·16 (1·05) −4·23 to −0·09†
IDEAS‡
Self-care item
Baseline 1 (0–2) 1 (0–2) ·· ··
6 months 1 (0–2) 1 (0–2) −0·001 (0·26) −0·50 to 0·50
12 months 1 (0–2) 1 (0–2) −0·86 (0·26) −1·36 to −0·35§
Interpersonal activities item
Baseline 2 (1–2) 1 (1–2) ·· ··
6 months 1 (1–2) 1 (1–2) 0·05 (0·25) −0·45 to 0·54
12 months 2 (1–2) 2 (1–2) −0·37 (0·34) −0·89 to 0·16
Communication and understanding item
Baseline 1 (1–2) 1 (1–2) ·· ··
6 months 1 (1–2) 1 (0·5–2) 0·39 (0·26) −0·11 to 0·90
12 months 2 (1–2) 2 (1–2) −0·47 (0·25) −0·97 to 0·26
Work item
Baseline 2 (1–4) 2 (1–4) ·· ··
6 months 2 (0–3) 2 (1–3) 0·39 (0·25) −0·09 to 0·87
12 months 2 (0–3) 2 (1–3) −0·30 (0·25) −0·79 to 0·18
Data are mean (SD) or median (IQR), unless otherwise indicated. PANSS=positive and negative syndrome scale. 
IDEAS=Indian disability evaluation assessment scale. *Linear regression including a random eﬀ ect for community 
health-care worker and covariance for baseline score and site. †p=0·04. ‡Ordinal logistic regression ﬁ tted with 
Generalized Linear Latent and Mixed Models (GLLAMM). Model includes a random eﬀ ect for community health-care 
worker and covariance for baseline score and site. §p=0·001.
Table 3: Changes in PANSS subscale and IDEAS domain scores over 12 months
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gastritis and vomiting, road accident, high fever, or 
cardiovascular disease; only one admission was at the 
Tamil Nadu site.
Discussion
Our ﬁ ndings show that the collaborative community-
based intervention including supervised community 
health workers was more eﬀ ective than were facility-
based services for people with moderate to severe 
schizophrenia. The overall beneﬁ ts of community-based 
plus facility-based care were modest at 12 months and 
were most evident in the reducing of disabilities 
associated with schizophrenia and in promotion of 
adherence with prescribed drugs. Additionally, we noted 
an overall trend for improvement in the severity of 
symptoms with the intervention; however, across the 
whole study, this trend was not statistically or clinically 
signiﬁ cantly diﬀ erent in comparison to facility-based 
care at 12 months.
We have described the association of PANSS score with 
the intervention (p=0·08) as modestly more eﬀ ective, 
which is in line with recommendations about this issue.21 
In view of this ﬁ nding, we focused on the eﬀ ect size and 
95% CI whilst showing p values, which is in line with 
CONSORT 2010 guidelines for reporting of ﬁ ndings from 
clinical trials.22 This symptom-related ﬁ nding is better 
than those from previous research about community 
mental health interventions in high-income countries, for 
which most studies tend to report improvements in 
service satisfaction, quality of life, and aspects of disability, 
but do not show symptom changes.23 Because the study 
intervention included components that were designed to 
improve self-care, structuring activities, social inter-
actions, and work ability, the greater eﬀ ectiveness of the 
intervention in reducing disability, compared with facility-
based care alone, is understandable.
The stigma-related ﬁ ndings are consistent with the 
explanation that facility-based care alone is eﬀ ective in 
reducing stigma and discrimination, and that there is little 
additional contribution from community-based care. The 
community-based plus facility-based care intervention did 
not produce any additional changes in caregivers 
understanding and knowledge of schizophrenia. This 
ﬁ nding is surprising and needs further exploration, 
especially from the available qualitative data available 
from a subset of participants. The absence of an 
association between caregivers’ burden and the greater 
reduction of disability levels in participants in the 
intervention group than in those in the control group is 
also unexpected. This ﬁ nding could show that an increased 
quantum of improvement in disability scores is needed to 
translate this improvement into matching improvement 
in caregiver burden.
The health economic ﬁ ndings showed that costs in the 
intervention group were on average greater than those 
in the control group, and that about a third of these 
additional costs were attributable to supervision. 
Eﬀ ective staﬀ  supervision is increasingly seen as a 
cornerstone for interventions including community 
health workers that are sustainable in the long term, and 
is fundamental to the delivery of WHO’s mhGAP 
Intervention Guide. The average greater cost for 
participants in the intervention group over the study 
period was almost INR 9500 (roughly I$500); therefore, 
a judgment should be taken as to the value in terms of 
the clinical and social improvements identiﬁ ed for a 
group of highly vulnerable people.
Recent randomised trials from low-income and middle-
income countries have reported the beneﬁ ts of family 
psychoeducation and adherence management in 
improvement of outcomes in people with 
schizophrenia.24–27 In all these trials, participants were 
recruited from hospital settings and the interventions 
were provided by specialists. By contrast, in our COPSI 
trial, supervised community health workers delivered the 
psychosocial intervention in the community. The 
ﬁ ndings of improved disability and adherence with 
additional psychosocial interventions are common across 
COPSI and these other studies.
Although the overall eﬀ ects of community-based plus 
facility-based care are moderate in scale, the primary 
outcomes diﬀ er greatly when disaggregated by site. This 
diﬀ erence is probably because of the methods of 
recruitment and the consequent characteristics of the 
participants. At both Satara and Goa, facility-based care 
Overall 
(n=246)
Collaborative 
community-
based care 
(n=162)
Facility-
based care 
(n=84)
Eﬀ ect measure 
(OR [95% CI])
Negative discrimination
Proportion with any negative discrimination* ·· ·· ·· 1·02 (0·54–1·92)
Baseline 105 
(43%)
67 (42%) 38 (45%) ··
12 months 73 (30%) 48 (30%) 25 (30%) ··
Anticipated discrimination†
Proportion with any anticipated discrimination ·· ·· ·· 1·31 (0·66–2·60)
Baseline 131 (53%) 92 (57%) 39 (46%) ··
12 months 92 (37%) 64 (40%) 28 (33%) ··
Alienation‡
Proportion with high alienation§ ·· ·· ·· 1·60 (0·82–3·12)
Baseline 133 
(48%)
88 (48%) 45 (48%) ··
12 months 77 (32%) 55 (34%) 22 (27%) ··
Proportion unwilling to disclose their illness ·· ·· ·· 2·77 (1·65–4·67)
Baseline 119 
(48%)
80 (49%) 39 (45%) ··
12 months 118 
(48%)
82 (51%) 36 (43%) ··
Data are n (%), unless otherwise indicated. OR=odds ratio. *Excludes seven participants who had missing items for all 
20 items on negative discrimination. †Excludes seven participants who had missing items for all four items on 
anticipated discrimination. ‡Excludes ﬁ ve participants who had missing data for all six items on alienation. §Alienation 
mean score less than 2·5.
Table 4: Stigma and discrimination outcomes for people with schizophrenia
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was provided by psychiatrists in well-established clinics 
and participants were therefore recruited from an existing 
pool of people with schizophrenia who were already 
receiving ongoing high-quality treatment. This ongoing 
usual care included many elements of community-based 
and facility-based care, albeit unstructured. In this 
context, community-based and facility-based care might 
have added little to the cumulative eﬀ ects of the facility-
based care and did not provide substantial additional 
beneﬁ ts. However, in Tamil Nadu, participants were 
recruited from a population-based sample and the 
additional community-based care intervention did provide 
substantial beneﬁ ts.
Were speciﬁ c, evidence-based interventions actually 
delivered to the intervention group? We ensured this 
delivery by ﬁ rst, following an independent assessment 
procedure for individualised clinical and social needs 
(using Camberwell assessment of needs). The team also 
adapted the manual to deliver the intervention according 
to the needs identiﬁ ed by each participant. Because 
these interventions were intensively supervised, we are 
reasonably conﬁ dent that community-based and facility-
based care delivered more than generic support from 
the community support worker and did in fact deliver 
interventions matched to individual needs.
Were all participants at least moderately severely 
disabled as speciﬁ ed in the study protocol? To ensure that 
ﬁ rst-contact patients did meet this criterion, details were 
collected by an experienced senior member of the clinical 
team. The psychiatrist then reviewed the information 
and did a detailed clinical assessment to decide if each 
participant fulﬁ lled the criteria for ICD-10 schizophrenia, 
and if they met the severity threshold by using criteria 
from the clinical global impression-schizophrenia scale 
for ICD-10 schizophrenia. Indeed, our trial was designed 
to include people with schizophrenia with a high overall 
severity for whom additional, community-based care 
would be justiﬁ able in the context of scarce resources. 
Thus, participants in the trial had a median duration of 
about 7 years of the illness, at least a moderate severity of 
symptoms and disabilities, and high levels of social 
adversity. For this group of people with long-term and 
severely disabling symptoms and various social 
problems, these modest improvements in disability and 
symptoms could be viewed as important outcomes. 
Indeed, it was striking that the outcome that improved 
the most disability matched the outcome that mattered 
the most to participants.
Clinical improvement in people with severe 
schizophrenia is often a gradual process and the fairly 
short duration of follow-up is a limitation of our trial. The 
longitudinal analysis of the disability data shows that 
signiﬁ cant improvements from the intervention happened 
between the 6 month and 12 month period, suggesting 
that a longer duration of follow-up is needed to show the 
additional beneﬁ ts of the psychosocial intervention.4
These ﬁ ndings are important because they suggest the 
potential use and limitations of the community-based 
and facility-based care intervention. With extrapolation 
from the ﬁ ndings in Tamil Nadu, and in view of the 
modest overall eﬀ ectiveness and the additional costs 
involved, community-based and facility-based care 
might be best deployed in a deﬁ ned catchment-area-
based population as an initial strategy of making care 
more accessible and equitable (by circumvention of 
barriers to treatment). Furthermore, the community-
based care intervention is clearly of restricted use in 
situations when the high-quality facility-based care is 
provided to a stable group of people with schizophrenia 
who are well engaged with their psychiatrists. The 
results also suggest that for people with moderate to 
severe schizophrenia, the interventions should focus on 
social and economic recovery and on changing the 
environmental barriers to care.
In the global mental health context, the results 
strengthen the case for consideration of the adoption of 
community-based plus facility-based care as an initial 
step in the provision of services to where they are needed 
and scarce (as is the case in many low-income and 
middle-income countries); this provision might need to 
be progressively supplemented by intensive or specialist 
services for patients who are diﬃ  cult to treat, as is 
common in high-income countries.28 In our trial, 
community health workers were trained for 6 weeks 
because the requirements of working in the context of a 
highly structured randomised trial are somewhat more 
Panel 2: Research in context
Systematic review
Several systematic reviews have been done to assess the evidence base for community 
services for people with schizophrenia in low-income and middle-income countries.30 
Except for some randomised trials of psychoeducational interventions from China, few 
trials from other low-income and middle-income countries have assessed community 
services rigorously. However, some recent randomised trials have tested the eﬀ ectiveness 
of psycho-educational interventions and adherence management strategies for people 
with schizophrenia and their caregivers from other low-income and middle-income 
countries.24–27 The results show that both psychoeducation and adherence management 
are eﬀ ective across a range of outcomes. However, there is an over-representation of 
studies done in specialist hospital settings and in settings where the interventions were 
delivered by specialist mental health workers, making generalisation of the results to 
community settings uncertain. As yet, no randomised trials are available of a 
community-based, multicomponent intervention delivered by community health 
workers from low-income and middle-income settings.
Interpretation
The community-based care intervention provided collaboratively by a team consisting of 
community health workers was more eﬀ ective for people with moderate to severe 
schizophrenia for reducing disability and improving adherence compared with usual, 
specialist care delivered from treatment facilities. Our ﬁ ndings provide rigorous evidence 
about the eﬀ ectiveness of use of supervised community health workers in provision of 
accessible, community-based services to people with schizophrenia—a strategy that has 
been advocated as a pragmatic method to scale up service coverage when specialist 
resources are scarce in low-income and middle-income countries.
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complicated than in real-life health programmes, 
whereas a briefer initial training programme of 3 weeks 
is likely to be more sustainable.
These ﬁ ndings have both strong internal validity and 
are potentially generalisable. The large sample size, the 
successful masking of allocation, the endpoint outcome 
data collected with fairly low rates of unmasking, the 
delivery of community-based plus facility-based care 
according to protocol across the sites, and the low 
attrition rates, add to the internal validity of the ﬁ ndings. 
The broad inclusion criteria and the fact that participants 
with a need for additional community care were recruited 
from real-world clinical settings across three diverse sites 
and practice arrangements in India all suggest that the 
ﬁ ndings of the trial are generalisable to similar settings 
in other low-income and middle-income countries.
These results add to the evidence base for the use of 
community health workers in the enhancement of access 
to services for people with schizophrenia in low-income 
and middle-income countries where specialist resources 
are few (panel 2). WHO and the Expert Policy Group of 
the Ministry of health in India have recommended use of 
non-specialist health workers to deliver community-
based psychosocial interventions to scale up services in 
low-income and middle-income countries.29. Within this 
global and national context, our ﬁ ndings are an important 
addition to the ongoing policy and advocacy eﬀ orts to 
make evidence-based services available for many more 
people with schizophrenia in low-income and middle 
income countries in the near future.
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